Statement: the primary and secondary trials report nausea as the most common adverse event.
Primary_evidence: Adverse Events 1:   Total: 17/65 (26.15%)   Febrile neutropenia 3/65 (4.62%)   Neutropenia 2/65 (3.08%)   Pancytopenia 1/65 (1.54%)   Thrombocytopenia 1/65 (1.54%)   Cardiac arrest 2/65 (3.08%)   Myocardial infarction 1/65 (1.54%)   Diarrhoea 5/65 (7.69%)   Stomatitis 1/65 (1.54%)   Vomiting 2/65 (3.08%)   Fatigue 1/65 (1.54%)   Jaundice 1/65 (1.54%)   Neutropenic infection 2/65 (3.08%)
Secondary_evidence: Adverse Events 1:   Total: 173/472 (36.65%)   Anaemia 6/472 (1.27%)   Febrile neutropenia 4/472 (0.85%)   Iron deficiency anaemia 1/472 (0.21%)   Leukopenia 2/472 (0.42%)   Neutropenia 2/472 (0.42%)   Thrombocytopenia 4/472 (0.85%)   Acute myocardial infarction 1/472 (0.21%)   Aortic valve incompetence 0/472 (0.00%)   Atrial fibrillation 2/472 (0.42%)   Cardiac arrest 1/472 (0.21%) Adverse Events 2:   Total: 40/238 (16.81%)   Anaemia 0/238 (0.00%)   Febrile neutropenia 1/238 (0.42%)   Iron deficiency anaemia 0/238 (0.00%)   Leukopenia 0/238 (0.00%)   Neutropenia 2/238 (0.84%)   Thrombocytopenia 0/238 (0.00%)   Acute myocardial infarction 0/238 (0.00%)   Aortic valve incompetence 1/238 (0.42%)   Atrial fibrillation 0/238 (0.00%)   Cardiac arrest 0/238 (0.00%)